Grifols SA Pref (GRLSbn)

Currency in EUR
9.325
-0.125(-1.32%)
Closed·
GRLSbn Scorecard
Full Analysis
Has a perfect Piotroski Score of 9
GRLSbn is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.2809.445
52 wk Range
5.5909.725
Key Statistics
Bid/Ask
9.32 / 9.325
Prev. Close
9.45
Open
9.44
Day's Range
9.28-9.445
52 wk Range
5.59-9.725
Volume
112.95K
Average Volume (3m)
177.01K
1-Year Change
34.23%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRLSbn Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.145
Upside
+8.79%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Grifols SA Pref News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Grifols SA Pref Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify – CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Employees
23833
Market
Spain

Compare GRLSbn to Peers and Sector

Metrics to compare
GRLSbn
Peers
Sector
Relationship
P/E Ratio
26.7x16.9x−0.5x
PEG Ratio
0.200.380.00
Price/Book
1.5x1.6x2.6x
Price / LTM Sales
1.1x2.5x3.3x
Upside (Analyst Target)
5.8%28.4%43.5%
Fair Value Upside
Unlock19.1%6.3%Unlock

Analyst Ratings

3 Buy
1 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 10.145
(+8.79% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.45%
Dividend Yield
1.29%
Industry Median 2.44%
Annualised payout
0.12
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
0.19 / 0.1998
Revenue / Forecast
1.89B / 1.90B
EPS Revisions
Last 90 days

GRLSbn Income Statement

People Also Watch

13.070
REP
+1.32%
3.1650
SABE
-0.63%
12.985
GRLS
+0.43%
41.250
ITX
-0.27%
7.4980
SAN
+0.24%

FAQ

What Stock Exchange Does Grifols Pref Trade On?

Grifols Pref is listed and trades on the Madrid Stock Exchange stock exchange.

What Is the Stock Symbol for Grifols Pref?

The stock symbol for Grifols Pref is "GRLSbn."

What Is the Grifols Pref Market Cap?

As of today, Grifols Pref market cap is 7.95B.

What Is Grifols Pref's Earnings Per Share (TTM)?

The Grifols Pref EPS (TTM) is 0.45.

When Is the Next Grifols Pref Earnings Date?

Grifols Pref will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is GRLSbn a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Grifols Pref Stock Split?

Grifols Pref has split 3 times.

How Many Employees Does Grifols Pref Have?

Grifols Pref has 23833 employees.

What is the current trading status of Grifols Pref (GRLSbn)?

As of 05 Aug 2025, Grifols Pref (GRLSbn) is trading at a price of 9.33, with a previous close of 9.45. The stock has fluctuated within a day range of 9.28 to 9.45, while its 52-week range spans from 5.59 to 9.73.

What Is Grifols Pref (GRLSbn) Price Target According to Analysts?

The average 12-month price target for Grifols Pref is EUR10.145, with a high estimate of EUR13.125 and a low estimate of EUR6.3. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +8.79% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.